The Quantellect read.As of Nov 19, 2026, 5 active firms cover Lyell Immunopharma Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $34.00 to $45.00, so the covering firms are broadly aligned. The average target of $40.60 sits 191% above the current $13.94. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.69 next quarter toward $-5.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$40.60
+191.4% upside
Average target across 5 active firms as of Nov 19, 2026 vs $13.94 current
Highest Target$45.00
Average Target$40.60
Lowest Target$34.00
Detailed analyst forecasts for LYEL
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate LYEL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LYEL EPS & revenue forecast
EPS · NEXT QUARTER
$-1.69
Range $-1.79 – $-1.61 · 5 analysts · +54% YoY
Next period, 5 analysts expect Lyell Immunopharma Inc to earn $-1.69 a share (range $-1.79 – $-1.61), versus $-1.10 a year earlier. Full-year consensus is $-6.69, growing to $-5.91 the year after.
REVENUE · NEXT QUARTER
$5.0K
Range $0 – $10.0K · 5 analysts · +150% YoY
Revenue is expected to reach $5.0K (range $0 – $10.0K), +150.0% year-over-year. Full-year consensus is $14.3K, rising to $9.9K next year.
Top analysts covering Lyell Immunopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LYEL.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$45.00+222.9% to target
Overall win rate
33%
+ Follow
#2
Gil Blum
Needham · Rank #409
Buy
$44.00+215.8% to target
Overall win rate
27%
+ Follow
#3
SW
Stephen Willey
Stifel · Rank #474
Buy
$36.00+158.3% to target
Overall win rate
29%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$34.00+144.0% to target
Overall win rate
29%
+ Follow
#5
Jason Zemansky
B of A Securities
Sell
$12.00-13.9% to target
Coverage
—
+ Follow
LYEL stock forecast FAQ
What is LYEL's average 12-month price target?+
The 5 active firms with a live target average $40.60 for Lyell Immunopharma Inc over the next 12 months, ranging from a $45.00 high to a $34.00 low, as of Nov 19, 2026.
Is LYEL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for LYEL?+
The Street-high target is $45.00 (HC Wainwright & Co.), and the Street-low is $34.00 (Citizens). The average of all 5 active-firm targets is $40.60.
How many active Wall Street firms cover LYEL?+
5 active firms have a recognized rating on Lyell Immunopharma Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LYEL?+
Among analysts who currently cover LYEL, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #305). Their current call is Buy with a $45.00 target.
What is Lyell Immunopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-1.69 per share (range $-1.79 – $-1.61) across 5 analysts. Full-year EPS is projected at $-6.69, rising to $-5.91 the following year.
How much revenue is Lyell Immunopharma Inc expected to report next quarter?+
Consensus revenue is $5.0K (range $0 – $10.0K). Full-year revenue is projected at $14.3K, growing to $9.9K next year.
Have analysts been upgrading or downgrading LYEL lately?+
As of Nov 19, 2026, 5 of 5 active firms rate LYEL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LYEL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.